Alterations in BCL-xL mRNA levels and BCL-xL/MCL-1 ratio in HCC patients. (A) BCL-xL and (B) BCL-xL/MCL-1 mRNA levels were measured by qPCR in healthy liver (n = 10) and in cirrhotic and tumoral tissue from HCC patients (n = 12) with Hepatitis C virus (HCV) and/or Ethanol (EtOH etiology. * p < 0.05 vs. control. (C) BCL-xL and (D) BCL-xL/MCL-1 mRNA levels were measured by qPCR in a commercial mRNA array with healthy liver (n = 8) and tumoral tissue from HCC patients in different stages (I-II, n = 14; IIIA-IV, n = 12). (E,F) Representation of survival probability depending on BCL-xL expression (blue, high; purple, low) in patients with liver and colorectal cancer, respectively.